Navigation Links
Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Date:9/30/2010

rapies are approved for the treatment of bipolar disorder, many individuals are unable to tolerate the treatment-related side effects, and incomplete clinical response, relapse and recurrence remain common clinical problems.  There are more than five million adults worldwide with bipolar disorder, an area of high unmet medical need due to the ineffectiveness and significant side effects of current therapies.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology.  We have a core competency in large-scale protein manufacturing and have out-licensed certain biologics intellectual property, which provide ongoing sources of revenue.  Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.  Additional information may be requested at www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property protection, product development, manufacturing plans and performance, project
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
2. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
3. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
8. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
11. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014 EHE ... exams with a nationwide physician network, today announced that ... has been named an EHE-certified preventive care center. Through ... Tarzana region now have greater access to ... "EHE is proud to add Dr. Abrams ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)...  Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying ... over $18.2 billion in 2023 in the United States ... , Italy , Spain , ... . TNF-alpha inhibitors will remain the leading drug class in ... will be constrained and patient shares will decline due to the ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... Newport Corporation (Nasdaq: NEWP ) today announced that it has ... to Dynasil Corporation (OTC Bulletin Board: DYSL), a provider of technology, ... markets. , , ... Hilger, based in Margate, UK, manufactures and sells a variety of ...
... N.Y. , July 20 As of ... standards applicable to devices that measure A1C (or glycated ... (NGSP) changed to +/-0.75% A1C, 95% CI, 4-10.0% A1C ... SELFCHECK devices, submits for annual NGSP certification each June ...
Cached Medicine Technology:Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 2Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 3New Standard of National Glycohemoglobin Standardization Program 2New Standard of National Glycohemoglobin Standardization Program 3
(Date:9/16/2014)... electronic activity monitors hold great promise in helping ... These increasingly sophisticated devices help the wearers improve ... bodily responses. This information is organized into companion ... the large and quickly growing market for these ... Branch at Galveston analyzed 13 of these activity ...
(Date:9/16/2014)... DC September 14, 2014 A ... everolimus-eluting stents (EES) and drug-eluting balloons (DEB) ... stents found that EES provided superior late ... , Findings were reported today at ... scientific symposium. Sponsored by the Cardiovascular Research ...
(Date:9/16/2014)... Seven heroes who have dramatically improved ... honored in New York City on November 6 by ... global recognition and funding program that honors individuals serving ... as the “Nobel Prize for Child Advocates,” this year’s ... that benefit children in countries around the world dealing ...
(Date:9/16/2014)... Tara Haelle HealthDay ... A new blood test is the first objective scientific way ... The test measures the levels of nine genetic indicators ... could also determine who will respond to cognitive behavioral therapy, ... and could show whether the therapy worked, Northwestern University researchers ...
(Date:9/16/2014)... Oncology (ASTRO) has selected C.M. Charlie Ma, PhD, Professor, ... Director of Medical Physics at Fox Chase Cancer ... members selected to receive the Fellow of ASTRO designation ... September 16, at the ASTRO,s 56th Annual Meeting in ... is a great honor and we are thrilled that ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
... Cancer Center, New York, and colleagues conducted a systematic ... harms of low-dose computerized tomography (LDCT) screening for lung ... "Most patients are diagnosed with advanced disease, resulting in ... "Renewed enthusiasm for lung screening arose with the advent ...
... - Treatment of obstructive sleep apnea (OSA) in children ... and executive function, according to a new study. ... in attention, cognition, and executive function," said lead author ... Sleep Center and University of Colorado Denver. "Our study ...
... More than 4.7 million Americans are bitten by dogs each ... than age 14, experts say. During National Dog Bite ... Pediatrics is joining with the American Veterinary Medical Association and ... They offer many tips to help parents protect their ...
... FRIDAY, May 18 (HealthDay News) -- One-third of homeless people in ... general population, a new study finds. It might seem that ... for weighing too little, according to the researchers at Harvard Medical ... Kingdom. But, the high rate of obesity among homeless people ...
... Since Sept. 11, it has become increasingly common ... or "infidels" to hell, but this has never ... State University professor who recently published a first-of-its-kind book ... Western writers believe condemnation and dehumanization of non-Muslims make ...
... May 18 (HealthDay News) -- Young people can easily buy ... wide range of advertising and marketing efforts from the alcohol ... the Center on Alcohol Marketing and Youth at the Johns ... alcohol messages, which may contribute to the 4,700 alcohol-related deaths ...
Cached Medicine News:Health News:Low-dose CT screening may benefit individuals at increased risk for lung cancer 2Health News:Treatment of childhood OSA reverses brain abnormalities 2Health News:Keeping Your Family Safe From Dog Bites 2Health News:One-Third of U.S. Homeless Population Is Obese: Study 2Health News:What does Islam say about the fate of others? 2Health News:Underage Drinkers Can Easily Order Alcohol From the Internet 2
Esophageal and Anorectal Solid State Catheter Adapter Cable for Polygraf ID...
... The ITREL 3 is a battery powered ... the U.S., ,Enterra™ Therapy is indicated ... vomiting associated with gastroparesis when conventional drug ... symptons for diabetic or idiopathic patients., ...
... diagnosis of influenza A and ... due to the availability of ... of influenza using Clearview Exact ... lead to reduced hospital stays, ...
... OMT test is a single use, qualitative, ... of antibodies to Human Immunodeficiency Virus Type ... human oral,mucosal transudate specimens. It is intended ... the clinical diagnosis of HIV,infection. This test ...
Medicine Products: